Naltrexone ER/Bupropion ER: A Review in Obesity Management.

Abstract

Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave(®), Mysimba(™)) is available as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of ≥ 30 kg/m(2) (i.e. obese) or a BMI of ≥ 27 kg/m(2) (i.e. overweight) in the presence of at least one bodyweight-related comorbidity, such as type 2 diabetes mellitus, hypertension or dyslipidaemia. In 56-week phase III trials in these patient populations, oral naltrexone ER/bupropion ER 32/360 mg/day was significantly more effective than placebo with regard to percentage bodyweight reductions from baseline and the proportion of patients who achieved bodyweight reductions of ≥ 5 and ≥ 10%. Significantly greater improvements in several cardiometabolic risk factors were also observed with naltrexone ER/bupropion ER versus placebo, as well as greater improvements in glycated haemoglobin levels in obese or overweight adults with type 2 diabetes. Naltrexone ER/bupropion ER was generally well tolerated in phase III trials, with nausea being the most common adverse event. Thus, naltrexone ER/bupropion ER 32/360 mg/day as an adjunct to a reduced-calorie diet and increased physical activity, is an effective and well tolerated option for chronic bodyweight management in obese adults or overweight adults with at least one bodyweight-related comorbidity.

• Authors: Sarah L Greig, Gillian M Keating
• Journal: Drugs (Drugs) Vol. 75 Issue 11 Pg. 1269-80 (Jul 2015) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 26105116 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Obesity Agents
• Delayed-Action Preparations
• Drug Combinations
• bupropion hydrochloride, naltrexone hydrochoride drug combination
• Bupropion
• Naltrexone

Topics

• Adult
• Animals
• Anti-Obesity Agents (administration & dosage, adverse effects, therapeutic use)
• Bupropion (administration & dosage, adverse effects, therapeutic use)
• Delayed-Action Preparations
• Drug Combinations
• Humans
• Naltrexone (administration & dosage, adverse effects, therapeutic use)
• Obesity (drug therapy)
• Overweight (drug therapy)